BA
HZNP

Bridgewater Associates’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Bridgewater Associates’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-77,311
Closed -$8.94M – 827
2023
Q3 		$8.94M Buy
77,311
+6,567
+9% +$706K 0.05% 252
2023
Q2 		$7.28M Sell
70,744
-104,900
-60% -$11.1M 0.04% 244
2023
Q1 		$19.2M Buy
175,644
+9,913
+6% +$1.1M 0.12% 143
2022
Q4 		$18.9M Sell
165,731
-109,526
-40% -$9.1M 0.1% 160
2022
Q3 		$17M Buy
275,257
+143,516
+109% +$10M 0.09% 173
2022
Q2 		$10.5M Buy
131,741
+119,735
+997% +$11.3M 0.04% 318
2022
Q1 		$1.26M Buy
+12,006
New +$1.17M 0.01% 773
2021
Q4 		– Sell
-3,985
Closed -$437K – 820
2021
Q3 		$437K Buy
+3,985
New +$414K ﹤0.01% 603

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.05B AUM 19.75% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Bridgewater Associates's HZNP Position: Q4 2023 in Review

Bridgewater Associates sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 77,311 shares — an estimated $8.94M sold.

Bridgewater Associates first reported a position in HZNP in Q3 2021 and held it in 8 quarters. The position peaked at $19.2M in Q1 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Bridgewater Associates reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Bridgewater Associates sold 77,311 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $8.94M.
  • Bridgewater Associates first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2021 and held it in 8 quarters.
  • Bridgewater Associates's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $19.2M in Q1 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Bridgewater Associates's 13F filing for Q4 2023, filed 14 Feb 2024.